Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)

被引:14
作者
Volta, Mattia [1 ,2 ,3 ]
Marti, Matteo [1 ,2 ,3 ]
McDonald, John [6 ]
Molinari, Stefano [1 ,2 ,3 ]
Camarda, Valeria [1 ,2 ,3 ]
Pela, Michela [4 ,5 ]
Trapella, Claudio [4 ,5 ]
Morari, Michele [1 ,2 ,3 ]
机构
[1] Univ Ferrara, Dept Expt & Clin Med, Pharmacol Sect, I-44100 Ferrara, Italy
[2] Univ Ferrara, Ctr Neurosci, I-44100 Ferrara, Italy
[3] Univ Ferrara, Natl Inst Neurosci, I-44100 Ferrara, Italy
[4] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[5] Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy
[6] Univ Leicester, Leicester Royal Infirm, Dept Cardiovasc Sci, Leicester, Leics, England
关键词
6-Hydroxydopamine; Microdialysis; Nociceptin/orphanin FQ; NOP receptor knock-out; Parkinson's disease; GF-4; VENTROMEDIAL THALAMIC NUCLEUS; NIGRA PARS RETICULATA; SUBSTANTIA-NIGRA; L-DOPA; IN-VITRO; EXPERIMENTAL PARKINSONISM; SPLICE VARIANTS; AMINO-ACIDS; ORPHANIN-FQ; RAT;
D O I
10.1016/j.peptides.2010.03.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study we provided a pharmacological characterization of the recently synthesized nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) and investigated its antiparkinsonian properties. GF-4 inhibited N/OFQ binding to CHOhNOP cell membranes (pK(i) 7.46), and antagonized N/OFQ effects in a calcium mobilization assay and electrically stimulated isolated tissues (pK(B) 7.27-7.82), showing a similar to 5-fold selectivity over classical opioid receptors. In vivo, GF-4 dually modulated stepping activity in wild-type mice, causing facilitation in the 0.01-10 mg/kg dose range and inhibition at 30 mg/kg. These effects were mediated by NOP receptors since GF-4 was ineffective in NOP receptor knock-out mice. Antiparkinsonian properties of GF-4 were investigated in 6-hydroxydopamine hemilesioned rats. GF-4 ameliorated akinesia, bradykinesia and overall gait ability in the 0.1-10 mg/kg dose range, but inhibited motor activity at 30 mg/kg. To investigate the circuitry underlying motor facilitating and inhibitory effects of GF-4, microdialysis coupled to behavioral testing (akinesia test) was performed. An anti-akinetic dose of GF-4 (1 mg/kg) reduced glutamate (GLU) and enhanced GABA release in SNr, while the pro-akinetic dose of GF-4 (30 mg/kg) evoked opposite effects. Moreover, the anti-akinetic dose of GF-4 reduced GABA and increased GLU release in ventro-medial thalamus, the pro-akinetic dose decreasing GABA without affecting GLU release in this area. We conclude that GF-4 is an effective NOP receptor antagonist able to attenuate parkinsonian-like symptoms in vivo via inhibition of the nigro-thalamic pathway. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:1194 / 1204
页数:11
相关论文
共 43 条
[1]   Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies [J].
Bigoni, R ;
Giuliani, S ;
Calo, G ;
Rizzi, A ;
Guerrini, R ;
Salvadori, S ;
Regoli, D ;
Maggi, CA .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (03) :160-167
[2]   Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression [J].
Brown, Jeffrey M. ;
Gouty, Shawn ;
Iyer, Varsha ;
Rosenberger, John ;
Cox, Brian M. .
JOURNAL OF NEUROCHEMISTRY, 2006, 98 (02) :495-505
[3]   [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor [J].
Calo, G ;
Rizzi, A ;
Rizzi, D ;
Bigoni, R ;
Guerrini, R ;
Marzola, G ;
Marti, M ;
McDonald, J ;
Morari, M ;
Lambert, DG ;
Salvadori, S ;
Regoli, D .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (02) :303-311
[4]   Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 [J].
Camarda, Valeria ;
Fischetti, Carmela ;
Anzellotti, Nicholas ;
Molinari, Paola ;
Ambrosio, Caterina ;
Kostenis, Evi ;
Regoli, Domenico ;
Trapella, Claudio ;
Guerrini, Remo ;
Severo, Salvadori ;
Calo, Girolamo .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 (06) :599-607
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Molecular cloning of the orphanin FQ receptor gene and differential tissue expression of splice variants in rat [J].
Currò, D ;
Yoo, JH ;
Anderson, M ;
Song, I ;
Del Valle, J ;
Owyang, C .
GENE, 2001, 266 (1-2) :139-145
[7]   DISINHIBITION AS A BASIC PROCESS IN THE EXPRESSION OF STRIATAL FUNCTIONS .2. THE STRIATO-NIGRAL INFLUENCE ON THALAMOCORTICAL CELLS OF THE VENTROMEDIAL THALAMIC NUCLEUS [J].
DENIAU, JM ;
CHEVALIER, G .
BRAIN RESEARCH, 1985, 334 (02) :227-233
[8]   Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats [J].
Di Benedetto, Manuela ;
Cavina, Chiara ;
D'Addario, Claudio ;
Leoni, Giorgia ;
Candeletti, Sanzio ;
Cox, Brian M. ;
Romualdi, Patrizia .
NEUROPHARMACOLOGY, 2009, 56 (04) :761-767
[9]   Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 [J].
Fischetti, Carmela ;
Camarda, Valeria ;
Rizzi, Anna ;
Pela, Michela ;
Trapella, Claudio ;
Guerrini, Remo ;
McDonald, John ;
Lambert, David G. ;
Salvadori, Severo ;
Regoli, Domenico ;
Calo, Girolamo .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 614 (1-3) :50-57
[10]   Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity [J].
Goto, Y ;
Arai-Otsuki, S ;
Tachibana, Y ;
Ichikawa, D ;
Ozaki, S ;
Takahashi, H ;
Iwasawa, Y ;
Okamoto, O ;
Okuda, S ;
Ohta, H ;
Sagara, T .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (03) :847-849